Table 1 Inclusion criteria for review
Criterion | Requirement for inclusion |
|---|---|
Population | Adult patients diagnosed with pulmonary arterial hypertension (PAH) according to the World Health Organization classification (Group 1)[11] |
Intervention | Endothelin receptor antagonist (ERA), phosphodiesterase 5 inhibitors (PDE5i), soluble guanylate cyclase stimulators, sGCs), prostacyclin analogs, or prostacyclin receptor agonists |
Comparator | The aforementioned targeted therapy drugs or placebo |
Outcomes | Incremental cost-effectiveness ratio (ICER) or incremental cost-utility ratio (ICUR) |
Study | Cost-effectiveness analysis, cost-utility analysis, cost‒benefit analysis, or cost- minimization analysis |
Other | Journal articles published in English and Chinese language |